TIAA FSB bought a new position in Thermo Fisher Scientific Inc (NYSE:TMO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 131,652 shares of the medical research company’s stock, valued at approximately $22,969,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after acquiring an additional 253 shares during the last quarter. Chicago Partners Investment Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth about $108,000. Cribstone Capital Management LLC increased its stake in Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after buying an additional 50 shares during the period. Sharkey Howes & Javer increased its stake in Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth about $113,000. Hedge funds and other institutional investors own 83.66% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (TMO) opened at $186.18 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $76,947.01, a P/E ratio of 21.09, a PEG ratio of 1.76 and a beta of 1.08. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.03 earnings per share. equities research analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.
COPYRIGHT VIOLATION NOTICE: “Tiaa Fsb Purchases New Holdings in Thermo Fisher Scientific Inc (TMO)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/131652-shares-in-thermo-fisher-scientific-inc-tmo-acquired-by-tiaa-fsb.html.
In other Thermo Fisher Scientific news, insider Daniel P. Shine sold 2,026 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $366,645.22. Following the completion of the sale, the insider now directly owns 20,682 shares in the company, valued at $3,742,821.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director C Martin Harris sold 360 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the sale, the director now owns 5,312 shares of the company’s stock, valued at $961,312.64. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is currently owned by corporate insiders.
A number of research analysts have commented on the stock. Jefferies Group LLC reissued a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a report on Thursday, September 7th. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reiterated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $205.71.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.